ELISA Kits, a Prototype Multiplex Electrochemoluminescent Assay

Comparison of Commercial ELISA Kits, a Prototype Multiplex Electrochemoluminescent Assay, and a Multiplex Bead-Based Immunoassay for Detecting a Urine-Based Bladder-Cancer-Associated Diagnostic Signature.
- The concentrations of the 10 proteins (A1AT; apolipoprotein E-APOE; angiogenin-ANG; carbonic anhydrase 9-CA9; interleukin 8-IL-8; matrix metalloproteinase 9-MMP-9; matrix metalloproteinase 10-MMP10; plasminogen activator inhibitor 1-PAI-1; syndecan-SDC1; and vascular endothelial growth factor-VEGF) were monitored using two prototype multiplex array platforms and an enzyme-linked immunosorbent assay (ELISA) according to the manufacturer’s technical specifications.
- The range for detecting each biomarker was improved in the multiplex assays, even though the lower limit of quantification (LLOQ) was typically lower in the commercial ELISA kits. The area under the receiver operating characteristics (AUROC) of the prototype multiplex assays was reported to be 0.97 for the multiplex bead-based immunoassay (MBA) and 0.86 for the multiplex electrochemoluminescent assay (MEA).
- The sensitivities and specificities for MBA were 0.93 and 0.95, respectively, and for MEA were 0.85 and 0.80, respectively. Accuracy, positive predictive values (PPV), and negative predictive values (NPV) for MBA were 0.94, 0.95, and 0.93, respectively, and for MEA were 0.83, 0.81, and 0.84, respectively. Based on these encouraging preliminary data, we believe that a multiplex protein array is a viable platform that can be utilized as an efficient and highly accurate tool to quantitate multiple proteins within biologic specimens.

PSMB8 Antibody |
|||
43134 | SAB | 100ul | EUR 319 |
PSMB8 Antibody |
|||
43134-100ul | SAB | 100ul | EUR 302.4 |
PSMB8 Antibody |
|||
BF0434 | Affbiotech | 200ul | EUR 540 |
PSMB8 Antibody |
|||
BF0434-100ul | Affinity Biosciences | 100ul | EUR 210 |
Description: WB,IHC,IF/ICC,ELISA |
PSMB8 Antibody |
|||
BF0434-200ul | Affinity Biosciences | 200ul | Ask for price |
Description: WB,IHC,IF/ICC,ELISA |
PSMB8 Antibody |
|||
BF0434-50ul | Affinity Biosciences | 50ul | EUR 150 |
Description: WB,IHC,IF/ICC,ELISA |
PSMB8 Antibody |
|||
1-CSB-PA775839 | Cusabio |
|
|
Description: A polyclonal antibody against PSMB8. Recognizes PSMB8 from Human. This antibody is Unconjugated. Tested in the following application: ELISA, WB, IHC;ELISA:1:2000-1:5000, WB:1:500-1:2000, IHC:1:25-1:100 |
PSMB8 Antibody |
|||
1-CSB-PA116429 | Cusabio |
|
|
Description: A polyclonal antibody against PSMB8. Recognizes PSMB8 from Human, Mouse. This antibody is Unconjugated. Tested in the following application: ELISA, WB, IHC;ELISA:1:1000-1:2000, WB:1:200-1:1000, IHC:1:25-1:100 |
PSMB8 Antibody |
|||
1-CSB-PA018886GA01HU | Cusabio |
|
|
Description: A polyclonal antibody against PSMB8. Recognizes PSMB8 from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: ELISA, WB, IHC, IF |
PSMB8 Antibody |
|||
1-CSB-PA018886LA01HU | Cusabio |
|
|
Description: A polyclonal antibody against PSMB8. Recognizes PSMB8 from Human. This antibody is Unconjugated. Tested in the following application: ELISA, IHC; Recommended dilution: IHC:1:20-1:200 |
PSMB8 Antibody |
|||
E043134 | EnoGene | 100μg/100μl | EUR 255 |
Description: Available in various conjugation types. |
PSMB8 Antibody |
|||
E314816 | EnoGene | 100ug/200ul | EUR 295 |
Description: Available in various conjugation types. |
PSMB8 Antibody |
|||
E97340 | EnoGene | 100ul | EUR 255 |
Description: Available in various conjugation types. |
PSMB8 Antibody |
|||
E94054 | EnoGene | 100μg | EUR 255 |
Description: Available in various conjugation types. |
PSMB8 Antibody |
|||
MBS5312424-01mL | MyBiosource | 0.1mL | EUR 1070 |
PSMB8 Antibody |
|||
MBS5312424-5x01mL | MyBiosource | 5x0.1mL | EUR 4655 |
PSMB8 Antibody |
|||
MBS7129229-005mL | MyBiosource | 0.05mL | EUR 190 |
PSMB8 Antibody |
|||
MBS7129229-01mL | MyBiosource | 0.1mL | EUR 270 |
PSMB8 Antibody |
|||
MBS7129229-5x01mL | MyBiosource | 5x0.1mL | EUR 1205 |
PSMB8 Antibody |
|||
MBS7129230-005mL | MyBiosource | 0.05mL | EUR 190 |
PSMB8 Antibody |
|||
MBS7129230-01mL | MyBiosource | 0.1mL | EUR 270 |
PSMB8 Antibody |
|||
MBS7129230-5x01mL | MyBiosource | 5x0.1mL | EUR 1205 |
PSMB8 Antibody |
|||
MBS7113266-005mL | MyBiosource | 0.05mL | EUR 190 |
PSMB8 Antibody |
|||
MBS7113266-01mL | MyBiosource | 0.1mL | EUR 270 |
PSMB8 Antibody |
|||
MBS7113266-5x01mL | MyBiosource | 5x0.1mL | EUR 1205 |
PSMB8 antibody |
|||
MBS9405580-01mL | MyBiosource | 0.1mL | EUR 420 |
PSMB8 antibody |
|||
MBS9405580-5x01mL | MyBiosource | 5x0.1mL | EUR 1740 |
PSMB8 Antibody |
|||
MBS9416351-01mL | MyBiosource | 0.1mL | EUR 305 |
PSMB8 Antibody |
|||
MBS9416351-5x01mL | MyBiosource | 5x0.1mL | EUR 1230 |
PSMB8 Antibody |
|||
MBS8500013-01mg | MyBiosource | 0.1mg | EUR 325 |
PSMB8 Antibody |
|||
MBS8500013-01mLAF405L | MyBiosource | 0.1mL(AF405L) | EUR 565 |
PSMB8 Antibody |
|||
MBS8500013-01mLAF405S | MyBiosource | 0.1mL(AF405S) | EUR 565 |
PSMB8 Antibody |
|||
MBS8500013-01mLAF610 | MyBiosource | 0.1mL(AF610) | EUR 565 |
PSMB8 Antibody |
|||
MBS8500013-01mLAF635 | MyBiosource | 0.1mL(AF635) | EUR 565 |
PSMB8 Polyclonal Antibody |
|||
A73468 | EpiGentek |
|
|
PSMB8 polyclonal antibody |
|||
BS8845 | Bioworld Biotech | 50 ul | EUR 358 |
Description: 1mg/ml in PBS with 0.02% sodium azide, 50% glycerol, pH7.2 |
PSMB8 polyclonal antibody |
|||
BS91127 | Bioworld Biotech | 50ul | EUR 398 |
Description: Rabbit IgG, 1mg/ml in PBS with 0.02% sodium azide, 50% glycerol, pH7.2 |
PSMB8 Polyclonal Antibody |
|||
E-AB-92394-120uL | Elabscience Biotech | 120uL | EUR 320 |
Description: Unconjugated |
PSMB8 Polyclonal Antibody |
|||
E-AB-92394-200uL | Elabscience Biotech | 200uL | EUR 530 |
Description: Unconjugated |
PSMB8 Polyclonal Antibody |
|||
E-AB-92394-60uL | Elabscience Biotech | 60uL | EUR 200 |
Description: Unconjugated |
PSMB8 Polyclonal Antibody |
|||
E-AB-92394-each | Elabscience Biotech | each | Ask for price |
Description: Unconjugated |
PSMB8 Polyclonal Antibody |
|||
E-AB-61655-120uL | Elabscience Biotech | 120uL | EUR 320 |
Description: Unconjugated |
PSMB8 Polyclonal Antibody |
|||
E-AB-61655-200uL | Elabscience Biotech | 200uL | EUR 530 |
Description: Unconjugated |
PSMB8 Polyclonal Antibody |
|||
E-AB-61655-60uL | Elabscience Biotech | 60uL | EUR 200 |
Description: Unconjugated |
PSMB8 Polyclonal Antibody |
|||
E-AB-61655-each | Elabscience Biotech | each | Ask for price |
Description: Unconjugated |
PSMB8 Conjugated Antibody |
|||
C43134 | SAB | 100ul | EUR 476.4 |
PSMB8 polyclonal antibody |
|||
BS78214 | Bioworld Biotech | 50ul | EUR 358 |
Description: 1mg/ml in PBS with 0.02% sodium azide, 50% glycerol, pH7.2 |
PSMB8 monoclonal antibody |
|||
MB66639 | Bioworld Biotech | 50ul | EUR 275 |
Description: Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide, pH 7.3. |
PSMB8 Polyclonal Antibody |
|||
MBS2538339-006mL | MyBiosource | 0.06mL | EUR 190 |
PSMB8 Polyclonal Antibody |
|||
MBS2538339-012mL | MyBiosource | 0.12mL | EUR 265 |
PSMB8 Polyclonal Antibody |
|||
MBS2538339-02mL | MyBiosource | 0.2mL | EUR 415 |
PSMB8 Polyclonal Antibody |
|||
MBS2538339-5x02mL | MyBiosource | 5x0.2mL | EUR 1835 |
PSMB8 Polyclonal Antibody |
|||
MBS2527805-002mL | MyBiosource | 0.02mL | EUR 140 |
PSMB8 Polyclonal Antibody |
|||
MBS2527805-006mL | MyBiosource | 0.06mL | EUR 180 |
PSMB8 Polyclonal Antibody |
|||
MBS2527805-012mL | MyBiosource | 0.12mL | EUR 260 |
PSMB8 Polyclonal Antibody |
|||
MBS2527805-02mL | MyBiosource | 0.2mL | EUR 405 |
PSMB8 Polyclonal Antibody |
|||
MBS2527805-5x02mL | MyBiosource | 5x0.2mL | EUR 1725 |
PSMB8 Polyclonal Antibody |
|||
MBS2528965-002mL | MyBiosource | 0.02mL | EUR 140 |
PSMB8 Polyclonal Antibody |
|||
MBS2528965-006mL | MyBiosource | 0.06mL | EUR 180 |
PSMB8 Polyclonal Antibody |
|||
MBS2528965-012mL | MyBiosource | 0.12mL | EUR 260 |
PSMB8 Polyclonal Antibody |
|||
MBS2528965-02mL | MyBiosource | 0.2mL | EUR 405 |
PSMB8 Polyclonal Antibody |
|||
MBS2528965-5x02mL | MyBiosource | 5x0.2mL | EUR 1725 |
PSMB8 Conjugated Antibody |
|||
MBS9451453-01mLAF350 | MyBiosource | 0.1mL(AF350) | EUR 480 |
PSMB8 Conjugated Antibody |
|||
MBS9451453-01mLAF405 | MyBiosource | 0.1mL(AF405) | EUR 480 |
PSMB8 Conjugated Antibody |
|||
MBS9451453-01mLAF488 | MyBiosource | 0.1mL(AF488) | EUR 480 |
PSMB8 Conjugated Antibody |
|||
MBS9451453-01mLAF555 | MyBiosource | 0.1mL(AF555) | EUR 480 |
PSMB8 Conjugated Antibody |
|||
MBS9451453-01mLBiotin | MyBiosource | 0.1mL(Biotin) | EUR 480 |
PSMB8 Polyclonal Antibody |
|||
RD84433A-120uL | Reddot Biotech | 120μL | EUR 360 |
Description: The proteasome is a multicatalytic proteinase complex with a highly ordered ring-shaped 20S core structure. The core structure is composed of 4 rings of 28 non-identical subunits; 2 rings are composed of 7 alpha subunits and 2 rings are composed of 7 beta subunits. Proteasomes are distributed throughout eukaryotic cells at a high concentration and cleave peptides in an ATP/ubiquitin-dependent process in a non-lysosomal pathway. An essential function of a modified proteasome, the immunoproteasome, is the processing of class I MHC peptides. This gene encodes a member of the proteasome B-type family, also known as the T1B family, that is a 20S core beta subunit. This gene is located in the class II region of the MHC (major histocompatibility complex). Expression of this gene is induced by gamma interferon and this gene product replaces catalytic subunit 3 (proteasome beta 5 subunit) in the immunoproteasome. Proteolytic processing is required to generate a mature subunit. Two alternative transcripts encoding two isoforms have been identified; both isoforms are processed to yield the same mature subunit. |
PSMB8 Polyclonal Antibody |
|||
RD84433A-200uL | Reddot Biotech | 200μL | EUR 630 |
Description: The proteasome is a multicatalytic proteinase complex with a highly ordered ring-shaped 20S core structure. The core structure is composed of 4 rings of 28 non-identical subunits; 2 rings are composed of 7 alpha subunits and 2 rings are composed of 7 beta subunits. Proteasomes are distributed throughout eukaryotic cells at a high concentration and cleave peptides in an ATP/ubiquitin-dependent process in a non-lysosomal pathway. An essential function of a modified proteasome, the immunoproteasome, is the processing of class I MHC peptides. This gene encodes a member of the proteasome B-type family, also known as the T1B family, that is a 20S core beta subunit. This gene is located in the class II region of the MHC (major histocompatibility complex). Expression of this gene is induced by gamma interferon and this gene product replaces catalytic subunit 3 (proteasome beta 5 subunit) in the immunoproteasome. Proteolytic processing is required to generate a mature subunit. Two alternative transcripts encoding two isoforms have been identified; both isoforms are processed to yield the same mature subunit. |
PSMB8 Polyclonal Antibody |
|||
RD84433A-60uL | Reddot Biotech | 60μL | EUR 204 |
Description: The proteasome is a multicatalytic proteinase complex with a highly ordered ring-shaped 20S core structure. The core structure is composed of 4 rings of 28 non-identical subunits; 2 rings are composed of 7 alpha subunits and 2 rings are composed of 7 beta subunits. Proteasomes are distributed throughout eukaryotic cells at a high concentration and cleave peptides in an ATP/ubiquitin-dependent process in a non-lysosomal pathway. An essential function of a modified proteasome, the immunoproteasome, is the processing of class I MHC peptides. This gene encodes a member of the proteasome B-type family, also known as the T1B family, that is a 20S core beta subunit. This gene is located in the class II region of the MHC (major histocompatibility complex). Expression of this gene is induced by gamma interferon and this gene product replaces catalytic subunit 3 (proteasome beta 5 subunit) in the immunoproteasome. Proteolytic processing is required to generate a mature subunit. Two alternative transcripts encoding two isoforms have been identified; both isoforms are processed to yield the same mature subunit. |
PSMB8 Antibody (N-term) |
|||
MBS9213569-008mL | MyBiosource | 0.08mL | EUR 210 |
PSMB8 Antibody (N-term) |
|||
MBS9213569-04mL | MyBiosource | 0.4mL | EUR 430 |
PSMB8 Antibody (N-term) |
|||
MBS9213569-5x04mL | MyBiosource | 5x0.4mL | EUR 1910 |
PSMB8 Antibody, HRP conjugated |
|||
1-CSB-PA018886LB01HU | Cusabio |
|
|
Description: A polyclonal antibody against PSMB8. Recognizes PSMB8 from Human. This antibody is HRP conjugated. Tested in the following application: ELISA |
PSMB8 Antibody, HRP Conjugated |
|||
MBS7113267-005mL | MyBiosource | 0.05mL | EUR 190 |
PSMB8 Antibody, HRP Conjugated |
|||
MBS7113267-01mL | MyBiosource | 0.1mL | EUR 270 |
PSMB8 Antibody, HRP Conjugated |
|||
MBS7113267-5x01mL | MyBiosource | 5x0.1mL | EUR 1205 |
PSMB8 Antibody, FITC conjugated |
|||
1-CSB-PA018886LC01HU | Cusabio |
|
|
Description: A polyclonal antibody against PSMB8. Recognizes PSMB8 from Human. This antibody is FITC conjugated. Tested in the following application: ELISA |
PSMB8 Antibody, FITC Conjugated |
|||
MBS7113268-005mL | MyBiosource | 0.05mL | EUR 190 |
Comparison of Rapid Anti-HCV Multi-sure Kit with Gold Standard ELISA.
To compare the diagnostic yield of Multi-sure rapid HCV (hepatitis C virus) kit with ELISA.Comparative study.Pakistan Health Research Council, specialised research center for gastroenterology and hepatology, from August 2016 to January 2017.A modified rapid anti-HCV kit was compared with ELISA. This rapid kit is multi-parameter qualitative immune chromatographic kit for the in-vitro detection of antibodies to HCV in human blood.
- Patients who came to PHRC, were tested using anti-HCV ELISA, and their test was run simultaneously on multi-sure HCV rapid kit were included in the study. Each positive and negative sample was included in this study. SPSS software was adapted for data analysis.A total of 420 samples were collected.
- Among them, 255 (61%) were of male and 165 (39%) were of female patients. Mean age was 35 ± 14.33 years. All the samples run for anti-HCV on ELISA were also run on multi-sure rapid kit. It is evident that 22.4% were reactive on ELISA and 23.6% were reactive on rapid kit, while 75.5% were non-reactive on ELISA and 68.1% were non-reactive on rapid kit.
- Borderline positive results were seen in 2.1% on ELISA and 5.0% on rapid kit. Sensitivity of rapid kit was 87.2%, specificity 89.3% with 82.8% positive predictive value and 98.9% negative predictive value.Multi-sure kit showed significantly, less non-reactive and more borderline results as compared to ELISA.
- Comparison of multi-sure rapid kit with ELISA showed that core antibody can be used as an alternate marker for ELISA. Other non-structural proteins including NS3, NS4 and NS5 were found to be less significant. So, it is concluded that this rapid kit may not be recommended as an alternative of ELISA, except for places where ELISA is not available.
Monitoring of infliximab trough levels and anti-infliximab antibodies in inflammatory bowel diseases: A comparison of three commercially available ELISA kits.
There are many studies presenting data of biologics and several ELISA kits commercially available for monitoring infliximab serum trough levels (s-IFXt) and anti-drug antibodies (ADAb). We propose to compare technical characteristics and results of three different assays on a cohort of 35 patients under infliximab (IFX) and suffering from inflammatory bowel disease (IBD).s-IFXt and ADAb were systematically measured with three ELISA kits: Lisa-Tracker® Duo infliximab (Theradiag®), Ridascreen® IFX Monitoring (R-Biopharm AG®) and Promonitor® IFX (Progenika Biopharma SA®).
The main technical features that differed between kits for measuring s-IFXt were: (i) TNF coating, (ii) immune complexes revelation strategy and/or (iii) interference with other anti-TNFα agents. For kits measuring ADAb, they were revelation steps and unit of results.
There was an excellent mathematical correlation of s-IFXt between assays however Bland-Altman analysis denoted (i) s-IFXt were on average 48 to 69% higher in Ridascreen® than in the other two assays, and (ii) elevated s-IFXt were higher with Promonitor® compared to Lisa-Tracker®.
As a consequence, there were some substantial discrepancies between assays for classification of s-IFXt into concentration ranges. Despite unstandardized units, pairwise qualitative comparison showed a perfect agreement between the three pairs of ADAb assays.
Our data show that the evaluated assays are not quantitatively interchangeable due to substantial variations in some results that could lead, for some patients, to divergent therapeutic decisions. We remind to be cautious when comparing study results issued from different kits and recommend using the same assay for the longitudinal follow-up of IBD patients